Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$40.28M
EBITDA Margin
-359.76%
TTM Avg
-259.71%
3Y Avg
-233.72%
5Y Avg
-2126.07%
Market Cap
$39.08M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
Market Cap
$38.35M
EBITDA Margin
-27375.58%
TTM Avg
-138216.12%
3Y Avg
-92142.37%
5Y Avg
-55460.65%
Market Cap
$42.97M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$37.76M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$43.96M
EBITDA Margin
-376.33%
TTM Avg
-387.64%
3Y Avg
-608.18%
5Y Avg
-1395.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.42M | N/A | N/A | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | -359.76% | -259.71% | -233.72% | -2126.07% |
| Nephros, Inc. (NEPH)vs › | $39.96M | 6.84% | 3.92% | -9.89% | -19.41% |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.08M | 6.14% | 3.48% | 3.86% | 5.21% |
| Precipio, Inc. (PRPO)vs › | $41.92M | 2.29% | -7.32% | -44.00% | -66.61% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | -0.99% | 4.72% | -25.09% | -32.37% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.76M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.96M | -376.33% | -387.64% | -608.18% | -1395.53% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.70M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
